Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.

Grade Last Price % Change Price Change
grade F 1.8929 5.42% 0.10
XTLB closed up 5.42 percent on Tuesday, September 17, 2019, on 6 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical XTLB trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 20 DMA Bearish 5.42%
Narrow Range Bar Range Contraction 5.42%
Gapped Down Weakness 5.42%
Narrow Range Bar Range Contraction 0.79%
Gapped Down Weakness 0.79%
Crossed Above 20 DMA Bullish 0.25%
Narrow Range Bar Range Contraction 0.25%

Older signals for XTLB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Natural Sciences Medication Pharmacy Pharmaceutical Products Schizophrenia Multiple Myeloma FDA Hepatitis C
Is XTLB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.855
52 Week Low 1.43
Average Volume 1,692
200-Day Moving Average 2.2
50-Day Moving Average 1.97
20-Day Moving Average 1.8503
10-Day Moving Average 1.8764
Average True Range 0.0989
ADX 8.32
+DI 35.4934
-DI 36.8805
Chandelier Exit (Long, 3 ATRs ) 1.8633
Chandelier Exit (Short, 3 ATRs ) 2.0067
Upper Bollinger Band 2.0139
Lower Bollinger Band 1.6867
Percent B (%b) 0.63
BandWidth 17.683619
MACD Line -0.0298
MACD Signal Line -0.0404
MACD Histogram 0.0106
Fundamentals Value
Market Cap 9.77 Million
Num Shares 5.16 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.72
Price-to-Sales 0.00
Price-to-Book 5.40
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.89
Resistance 3 (R3) 1.89 1.89 1.89
Resistance 2 (R2) 1.89 1.89 1.89 1.89
Resistance 1 (R1) 1.89 1.89 1.89 1.89 1.89
Pivot Point 1.89 1.89 1.89 1.89 1.89
Support 1 (S1) 1.89 1.89 1.89 1.89 1.89
Support 2 (S2) 1.89 1.89 1.89 1.89
Support 3 (S3) 1.89 1.89 1.89
Support 4 (S4) 1.89